YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis

Histopathology

Volumn 57, Issue 3, 2010, Pages 371-383

  Richter, Benedikte ^a   Roslind, Anne ^a   Hesse, Ulrik ^b   Nordling, Jørgen ^a   Johansen, Julia Sidenius ^a   Horn, Thomas ^a   Hansen, Alastair Bierre ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DANISH MEDICINES AGENCY   (Denmark)

Author keywords

biomarkers; fibrosis; interstitial cystitis; mast cells; YKL 40 protein human

Indexed keywords

BIOLOGICAL MARKER; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CAPACITY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTALGIA; CYSTOSCOPY; DETRUSOR MUSCLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CYSTITIS; MACROPHAGE; MALE; MAST CELL; MYOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; SERUM; URINE;

ADULT; AGED; CYSTITIS, INTERSTITIAL; EUROPE; FEMALE; FIBROSIS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS; MALE; MAST CELLS; MIDDLE AGED; PATHOLOGY; SOCIETIES, MEDICAL; URINARY BLADDER;

EID: 77956624663     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03640.x     Document Type: Article

References (53)

1. van de Merwe JP, Nordling J, Bouchelouche P et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 2008 53 60 67.
2. Nordling J, Anjum FH, Bade J et al. Primary evaluation of patients suspected of having interstitial cystitis. Eur. Urol. 2004 45 662 669.
3. Mayer R. Interstitial cystitis pathogenesis and treatment. Curr. Opin. Infect. Dis. 2007 20 77 82.
4. Christmas TJ, Smith GL, Rode J. Detrusor myopathy: an accurate predictor of bladder hypocompliance and contracture in interstitial cystitis. Br. J. Urol. 1996 78 862 865.
5. Richter B, Hesse U, Hansen AB, Horn T, Mortensen SO, Nordling J. Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis. BJU Int. 2010 105 660 667.
6. Rosenblatt RL. Lung transplantation in cystic fibrosis. Respir. Care 2009 54 777 786.
7. Svegliati-Baroni G, De Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int. 2008 28 1052 1064.
8. Reshetnyak VI. Concept on the pathogenesis and treatment of primary biliary cirrhosis. World J. Gastroenterol. 2006 12 7250 7262.
9. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am. J. Gastroenterol. 2007 102 439 448.
10. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J. Hepatol. 2003 39 179 186.
11. Johansen JS, Christoffersen P, Moller S et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol. 2000 3 911 920.
12. Berres ML, Papen S, Pauels K et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J. Hepatol. 2009 50 370 376.
13. Volck B, Johansen JS, Stoltenberg M et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001 9 203 214.
14. Johansen JS, Stoltenberg M, Hansen M et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999 38 618 626.
15. Johansen JS, Kirwan Jr. Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand. J. Rheumatol. 2001 30 297 304.
16. Harvey S, Weisman M, O'Dell J et al. Chondrex: new marker of joint disease. Clin. Chem. 1998 44 509 516.
17. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron. Artery Dis. 2007 18 391 396.
18. Boot RG, van Achterberg TA, van Aken BE et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 1999 19 687 694.
19. Chupp GL, Lee CG, Jarjour N et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 2007 357 2016 2027.
20. Ober C, Tan Z, Sun Y et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N. Engl. J. Med. 2008 358 1682 1691.
21. Letuve S, Kozhich A, Arouche N et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J. Immunol. 2008 181 5167 5173.
22. Lee CG, Hartl D, Lee GR et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J. Exp. Med. 2009 206 1149 1166.
23. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol. Biol. 2009 511 159 184.
24. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem. J. 2002 365 119 126.
25. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J. Biol. Chem. 2006 281 21082 21095.
26. Ustinova EE, Gutkin DW, Fraser MO, Pezzone MA. Neurogenic cystitis induced by colonic irritation results in increased urothelial permeability that parallels bladder mastocytosis and hyperactivity. J. Urol. 2008 179 (Suppl. 4 60.
27. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007 69 (Suppl. 4 34 40.
28. Larsen S, Thompson SA, Hald T et al. Mast cells in interstitial cystitis. Br. J. Urol. 1982 54 283 286.
29. Christmas TJ, Rode J. Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 1991 68 473 478.
30. Larsen MS, Mortensen S, Nordling J, Horn T. Quantifying mast cells in bladder pain syndrome by immunohistochemical analysis. BJU Int. 2008 102 204 207.
31. Roslind A, Johansen JS, Junker N et al. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl. Immunohistochem. Mol. Morphol. 2007 15 371 381.
32. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am. J. Surg. Pathol. 2001 25 1204 1207.
33. Gundersen HJG, Bendtsen T, Korbo L et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988 96 379 394.
34. Roslind A, Balslev E, Kruse H, Staergaard B, Horn T. Subcellular localization of YKL-40 in normal and malignant epithelial cells of the breast. Ultrastruct. Pathol. 2008 32 101 106.
35. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK. Stability of YKL-40 concentration in blood samples. Scand. J. Clin. Lab. Invest. 2000 60 247 251.
36. Johansen JS, Lottenburger T, Nielsen HJ et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 2008 17 2603 2608.
37. Forrest JB, Moldwin R. Diagnostic options for early identification and management of interstitial cystitis/painful bladder syndrome. Int. J. Clin. Pract. 2008 62 1926 1934.
38. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 2006 53 172 209.
39. Ringsholt M, Hogdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues - an immunohistochemical study. J. Mol. Histol. 2007 38 33 43.
40. Iwata T, Kuwajima M, Sukeno A et al. YKL-40 secreted from adipose tissue inhibits degradation of type I collagen. Biochem. Biophys. Res. Commun. 2009 388 511 516.
41. Hogdall EV, Ringsholt M, Hogdall CK et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009 9 8.
42. Roslind A, Knoop AS, Jensen MB et al. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res. Treat. 2008 112 275 285.
43. Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005 48 223 231.
44. Roslind A, Johansen JS, Christensen IJ et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int. J. Cancer 2008 122 857 863.
45. Volck B, Price PA, Johansen JS et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians 1998 110 351 360.
46. Leitinger N. 'Obese' smooth muscle cells fail to assemble collagen fibrils. Circ. Res. 2009 104 826 828.
47. Frontini MJ, O'Neil C, Sawyez C, Chan BM, Huff MW, Pickering JG. Lipid incorporation inhibits Src-dependent assembly of fibronectin and type I collagen by vascular smooth muscle cells. Circ. Res. 2009 104 832 841.
48. Howard PS, Renfrow D, Schechter NM, Kucich U. Mast cell chymase is a possible mediator of neurogenic bladder fibrosis. Neurourol. Urodyn. 2004 23 374 382.
49. Kastrup J, Hald T, Larsen S, Nielsen VG. Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis. Br. J. Urol. 1983 55 495 500.
50. Lynes WL, Flynn SD, Shortliffe LD et al. Mast cell involvement in interstitial cystitis. J. Urol. 1987 138 746 752.
51. Wyndaele JJ, Van DJ, Toussaint N. Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines. Scand. J. Urol. Nephrol. 2009 43 471 475.
52. Dundore PA, Schwartz AM, Semerjian H. Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. J. Urol. 1996 155 885 887.
53. Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007 69 (Suppl. 4 24 33.